Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Woodline Partners LP

Woodline Partners LP decreased its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 49.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 530,582 shares of the company's stock after selling 524,700 shares during the quarter. Woodline Partners LP owned approximately 0.74% of Zentalis Pharmaceuticals worth $1,608,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vident Advisory LLC purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter worth approximately $45,000. State of Wyoming lifted its stake in Zentalis Pharmaceuticals by 124.6% during the fourth quarter. State of Wyoming now owns 34,716 shares of the company's stock worth $105,000 after purchasing an additional 19,262 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter worth approximately $52,000. Nuveen Asset Management LLC lifted its stake in Zentalis Pharmaceuticals by 35.2% during the fourth quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company's stock worth $1,943,000 after purchasing an additional 167,062 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Zentalis Pharmaceuticals by 8.1% during the fourth quarter. Millennium Management LLC now owns 957,563 shares of the company's stock worth $2,901,000 after purchasing an additional 71,477 shares during the last quarter.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers acquired 21,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were acquired at an average price of $1.40 per share, with a total value of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares in the company, valued at approximately $393,668.80. The trade was a 8.07% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on ZNTL. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday, January 30th. Finally, Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Zentalis Pharmaceuticals has an average rating of "Hold" and a consensus target price of $8.24.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock traded down $0.03 during trading hours on Friday, hitting $1.23. The stock had a trading volume of 174,527 shares, compared to its average volume of 1,551,551. The stock has a market capitalization of $88.14 million, a price-to-earnings ratio of -0.49 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $13.00. The stock's fifty day moving average is $1.33 and its two-hundred day moving average is $2.19.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.